logo banner home news contact
nav

news

events

 

News

Return to News

Argos Therapeutics Data From Kidney Cancer Vaccine Phase I/II Study To Be Presented At Two Upcoming Oncology Conferences


Durham, NC- October 20, 2005 - Argos Therapeutics, a pioneer in immunotherapy, today announced that final results of its corporate Phase I/II clinical trial that tested an RNA-loaded autologous dendritic cell vaccine for kidney (renal) cancer will be presented during two upcoming conferences:

• The Fourth International Kidney Cancer Symposium

• The American Association of Cancer Research-National Cancer Institute-European Organization for Research and Treatment of Cancer (AACR-NCI-EORTC) International Conference

Argos scientists will conduct an oral and poster presentation on trial data at the Fourth International Kidney Cancer Symposium, sponsored by the Kidney Cancer Association in conjunction with the Cleveland Clinic Foundation: The Taussig Cancer Center. The conference will be held on October 21 – 23, 2005 at the Palmer House Hilton in Chicago, Illinois.

Argos will also present results at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications, to be held on November 14 – 18, 2005 at the Pennsylvania Convention Center in Philadelphia, Pennsylvania.

The Phase I/II trial for a total tumor RNA-loaded dendritic cell vaccine focused on patients newly diagnosed with metastatic renal cell cancer, and was conducted at five clinical sites in the United States and Canada. Trial objectives included demonstrating the safety and commercial feasibility of processing dendritic cells at a central manufacturing facility, with delivery of the vaccine to multiple clinical sites. Data will be strictly embargoed until presentation times at the respective conferences.

Argos Therapeutics
Argos Therapeutics, Inc., is dedicated to becoming a market leader in the field of immunotherapy. By using proprietary technology, proven therapeutic methods, and expertise in dendritic cell biology, Argos is developing the next generation of therapies in the areas of oncology, infectious diseases, autoimmune disorders and transplantation.

Argos’ focus is bringing to market therapeutic options that not only offer new promise for treatment of intractable diseases, but also an improved safety profile and better patient quality of life during treatment. Please visit Argos at www.argostherapeutics.com.

# # #

Editor Contacts:
Kellie Nolan, Gibbs & Soell, Inc.
Tel: 847-519-9150
[email protected]
Or,
Anna Munoz, Gibbs & Soell, Inc.
Phone: 919-870-5718
[email protected]